KU Leuven

The <b>metafor</b> package provides functions for conducting meta-analyses in <b>R</b>. The package includes functions for fitting the meta-analytic fixed- and random-effects models and allows for the inclusion of moderators variables (study-level covariates) in these models. Meta-regression analyses with continuous and categorical moderators can be conducted in this way. Functions for the Mantel-Haenszel and Peto's one-step method for meta-analyses of 2 x 2 table data are also available. Finally, the package provides various plot functions (for example, for forest, funnel, and radial plots) and functions for assessing the model fit, for obtaining case diagnostics, and for tests of publication bias.

Bayesian inference of phylogeny using Markov chain Monte Carlo (MCMC) plays a central role in understanding evolutionary history from molecular sequence data. Visualizing and analyzing the MCMC-generated samples from the posterior distribution is a key step in any non-trivial Bayesian inference. We present the software package Tracer (version 1.7) for visualizing and analyzing the MCMC trace files generated through Bayesian phylogenetic inference. Tracer provides kernel density estimation, multivariate visualization, demographic trajectory reconstruction, conditional posterior distribution summary, and more. Tracer is open-source and available at http://beast.community/tracer.

The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles ("MISEV") guidelines for the field in 2014. We now update these "MISEV2014" guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV-associated functional activities. Finally, a checklist is provided with summaries of key points.

BACKGROUND: Hyperglycemia and insulin resistance are common in critically ill patients, even if they have not previously had diabetes. Whether the normalization of blood glucose levels with insulin therapy improves the prognosis for such patients is not known. METHODS: We performed a prospective, randomized, controlled study involving adults admitted to our surgical intensive care unit who were receiving mechanical ventilation. On admission, patients were randomly assigned to receive intensive insulin therapy (maintenance of blood glucose at a level between 80 and 110 mg per deciliter [4.4 and 6.1 mmol per liter]) or conventional treatment (infusion of insulin only if the blood glucose level exceeded 215 mg per deciliter [11.9 mmol per liter] and maintenance of glucose at a level between 180 and 200 mg per deciliter [10.0 and 11.1 mmol per liter]). RESULTS: At 12 months, with a total of 1548 patients enrolled, intensive insulin therapy reduced mortality during intensive care from 8.0 percent with conventional treatment to 4.6 percent (P<0.04, with adjustment for sequential analyses). The benefit of intensive insulin therapy was attributable to its effect on mortality among patients who remained in the intensive care unit for more than five days (20.2 percent with conventional treatment, as compared with 10.6 percent with intensive insulin therapy, P=0.005). The greatest reduction in mortality involved deaths due to multiple-organ failure with a proven septic focus. Intensive insulin therapy also reduced overall in-hospital mortality by 34 percent, bloodstream infections by 46 percent, acute renal failure requiring dialysis or hemofiltration by 41 percent, the median number of red-cell transfusions by 50 percent, and critical-illness polyneuropathy by 44 percent, and patients receiving intensive therapy were less likely to require prolonged mechanical ventilation and intensive care. CONCLUSIONS: Intensive insulin therapy to maintain blood glucose at or below 110 mg per deciliter reduces morbidity and mortality among critically ill patients in the surgical intensive care unit.

Context. We present the second Gaia data release, Gaia DR2, consisting of astrometry, photometry, radial velocities, and information on astrophysical parameters and variability, for sources brighter than magnitude 21. In addition epoch astrometry and photometry are provided for a modest sample of minor planets in the solar system. Aims. A summary of the contents of Gaia DR2 is presented, accompanied by a discussion on the differences with respect to Gaia DR1 and an overview of the main limitations which are still present in the survey. Recommendations are made on the responsible use of Gaia DR2 results. Methods. The raw data collected with the Gaia instruments during the first 22 months of the mission have been processed by the Gaia Data Processing and Analysis Consortium (DPAC) and turned into this second data release, which represents a major advance with respect to Gaia DR1 in terms of completeness, performance, and richness of the data products. Results. Gaia DR2 contains celestial positions and the apparent brightness in G for approximately 1.7 billion sources. For 1.3 billion of those sources, parallaxes and proper motions are in addition available. The sample of sources for which variability information is provided is expanded to 0.5 million stars. This data release contains four new elements: broad-band colour information in the form of the apparent brightness in the G BP (330–680 nm) and G RP (630–1050 nm) bands is available for 1.4 billion sources; median radial velocities for some 7 million sources are presented; for between 77 and 161 million sources estimates are provided of the stellar effective temperature, extinction, reddening, and radius and luminosity; and for a pre-selected list of 14 000 minor planets in the solar system epoch astrometry and photometry are presented. Finally, Gaia DR2 also represents a new materialisation of the celestial reference frame in the optical, the Gaia -CRF2, which is the first optical reference frame based solely on extragalactic sources. There are notable changes in the photometric system and the catalogue source list with respect to Gaia DR1, and we stress the need to consider the two data releases as independent. Conclusions. Gaia DR2 represents a major achievement for the Gaia mission, delivering on the long standing promise to provide parallaxes and proper motions for over 1 billion stars, and representing a first step in the availability of complementary radial velocity and source astrophysical information for a sample of stars in the Gaia survey which covers a very substantial fraction of the volume of our galaxy.

Gaia is a cornerstone mission in the science programme of the EuropeanSpace Agency (ESA). The spacecraft construction was approved in 2006, following a study in which the original interferometric concept was changed to a direct-imaging approach. Both the spacecraft and the payload were built by European industry. The involvement of the scientific community focusses on data processing for which the international Gaia Data Processing and Analysis Consortium (DPAC) was selected in 2007. Gaia was launched on 19 December 2013 and arrived at its operating point, the second Lagrange point of the Sun-Earth-Moon system, a few weeks later. The commissioning of the spacecraft and payload was completed on 19 July 2014. The nominal five-year mission started with four weeks of special, ecliptic-pole scanning and subsequently transferred into full-sky scanning mode. We recall the scientific goals of Gaia and give a description of the as-built spacecraft that is currently (mid-2016) being operated to achieve these goals. We pay special attention to the payload module, the performance of which is closely related to the scientific performance of the mission. We provide a summary of the commissioning activities and findings, followed by a description of the routine operational mode. We summarise scientific performance estimates on the basis of in-orbit operations. Several intermediate Gaia data releases are planned and the data can be retrieved from the Gaia Archive, which is available through the Gaia home page.

BACKGROUND: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer. METHODS: We randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks or gemcitabine monotherapy (1000 mg per square meter) weekly for 7 of 8 weeks (cycle 1) and then on days 1, 8, and 15 every 4 weeks (cycle 2 and subsequent cycles). Patients received the study treatment until disease progression. The primary end point was overall survival; secondary end points were progression-free survival and overall response rate. RESULTS: A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was 8.5 months in the nab-paclitaxel-gemcitabine group as compared with 6.7 months in the gemcitabine group (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was 5.5 months in the nab-paclitaxel-gemcitabine group, as compared with 3.7 months in the gemcitabine group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; P<0.001); the response rate according to independent review was 23% versus 7% in the two groups (P<0.001). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days. CONCLUSIONS: In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).

Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been complicated by histological and aetiological heterogeneity. Here we describe a comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project. We propose a molecular classification dividing gastric cancer into four subtypes: tumours positive for Epstein–Barr virus, which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2); microsatellite unstable tumours, which show elevated mutation rates, including mutations of genes encoding targetable oncogenic signalling proteins; genomically stable tumours, which are enriched for the diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins; and tumours with chromosomal instability, which show marked aneuploidy and focal amplification of receptor tyrosine kinases. Identification of these subtypes provides a roadmap for patient stratification and trials of targeted therapies. The Cancer Genome Atlas reports on molecular evaluation of 295 primary gastric adenocarcinomas and proposes a new classification of gastric cancers into 4 subtypes, which should help with clinical assessment and trials of targeted therapies. This contribution from The Cancer Genome Atlas (TCGA) project describes the molecular evaluation of 295 primary gastric adenocarcinomas. Based on the results, the authors propose a novel classification separating gastric cancers into four subtypes according to: Epstein–Barr virus positive status, microsatellite instability, chromosomal instability or genomic stability. Given the histologic and etiologic heterogeneity of gastric cancer identification of these subtypes, using a schema that can readily be applied to patient samples should help with patient stratification and trials of targeted therapies.

In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes. For example, a key point that needs to be emphasized is thatthere is a difference between measurements that monitor the numbers or volume of autophagic elements (e.g., autophagosomes or autolysosomes) at any stage of the autophagic process versus those that measure flux through the autophagy pathway (i.e., the completeprocess including the amount and rate of cargo sequestered and degraded). In particular, a block in macroautophagy that results in autophagosome accumulation must be differentiated from stimuli that increase autophagic activity, defined as increasedautophagy induction coupled with increased delivery to, and degradation within, lysosomes (inmost higher eukaryotes and some protists such as Dictyostelium) or the vacuole (in plants and fungi). In other words, it is especially important that investigators new to the field understand that the appearance of more autophagosomes does not necessarily equate with more autophagy. In fact, in manycases, autophagosomes accumulate because of a block in trafficking to lysosomes without a concomitant change in autophagosome biogenesis, whereas an increase in autolysosomes may reflect a reduction in degradative activity. It is worth emphasizing here that lysosomal digestion is a stage of autophagy and evaluating its competence is a crucial part of the evaluation of autophagic flux, or complete autophagy. Here, we present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as forreviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. These guidelines are not meant to be a formulaic set of rules, because the appropriate assays depend in part on the question being asked and the system being used. In addition, we emphasize that no individual assay is guaranteed to be the most appropriate one in every situation, and we strongly recommend the use of multipleassays to monitor autophagy. Along these lines, because of the potential for pleiotropic effects due to blocking autophagy through genetic manipulation, it is imperative to target by gene knockout or RNA interference more than one autophagyrelated protein. In addition, some individual Atg proteins, or groups of proteins, are involved in other cellular pathways implying that not all Atg proteins can be used as a specific marker for an autophagic process. In these guidelines, we consider these various methods of assessing autophagy and what information can, or cannot, be obtained from them. Finally, by discussing the merits and limits of particular assays, we hope to encourage technical innovation in the field.

Table of Contents Introduction Principles New aspects Epidemiological aspects Relationship of blood pressure to cardiovascular and renal damage Definition and classification of hypertension Prevalence of hypertension Hypertension and total cardiovascular risk Assessment of total cardiovascular risk Limitations Summary of recommendations on total cardiovascular risk assessment Diagnostic evaluation Bood pressure measurement Office or clinic blood pressure Out-of-office blood pressure White-coat (or isolated office) hypertension and masked (or isolated ambulatory) hypertension Clinical indications for out-of-office blood pressure Blood pressure during exercise and laboratory stress Central blood pressure Medical history Physical examination Summary of recommendations on blood pressure measurement, history, and physical examination Laboratory investigations Genetics Searching for asymptomatic organ damage Heart Blood vessels Kidney Fundoscopy Brain Clinical value and limitations Summary of recommendations on the search for asymptomatic organ damage, cardiovascular disease, and chronic kidney disease Searching for secondary forms of hypertension Treatment approach Evidence favouring therapeutic reduction of high blood pressure When to initiate antihypertensive drug treatment Recommendations of previous Guidelines Grade 2 and 3 hypertension and high-risk grade 1 hypertension Low-to-moderate risk, grade 1 hypertension Isolated systolic hypertension in youth Grade 1 hypertension in the elderly High normal blood pressure Summary of recommendations on initiation of antihypertensive drug treatment Blood pressure treatment targets Recommendations of previous Guidelines Low-to-moderate risk hypertensive patients Hypertension in the elderly High-risk patients The ‘lower the better’ vs. the J-shaped curve hypothesis Evidence on target blood pressure from organ damage studies Clinic vs. home and ambulatory blood pressure targets Summary of recommendations on blood pressure targets in hypertensive patients Treatment strategies Lifestyle changes Salt restriction Moderation of alcohol consumption Other dietary changes Weight reduction Regular physical exercise Smoking cessation Summary of recommendations on adoption of lifestyle changes Pharmacological therapy Choice of antihypertensive drugs Monotherapy and combination therapy Summary of recommendations on treatment strategies and choice of drugs Treatment strategies in special conditions White-coat hypertension Masked hypertension Summary of recommendations on treatment strategies in white-coat and masked hypertension Elderly Summary of recommendations on antihypertensive treatment strategies in the elderly Young adults Women Oral contraceptives Hormone replacement therapy Pregnancy Long-term cardiovascular consequences in gestational hypertension Summary of recommendations on treatment strategies in hypertensive women Diabetes mellitus Summary of recommendations on treatment strategies in patients with diabetes Metabolic syndrome Summary of recommendations on treatment strategies in hypertensive patients with metabolic syndrome Obstructive sleep apnoea Diabetic and non-diabetic nephropathy Summary of recommendations on therapeutic strategies in hypertensive patients with nephropathy Chronic kidney disease stage 5D Cerebrovascular disease Acute stroke Previous stroke or transient ischaemic attack Cognitive dysfunction and white matter lesions Summary of recommendations on therapeutic strategies in hypertensive patients with cerebrovascular disease Heart disease Coronary heart disease Heart failure Atrial fibrillation Left ventricular hypertrophy Summary of recommendations on therapeutic strategies in hypertensive patients with heart disease Atherosclerosis, arteriosclerosis, and peripheral artery disease Carotid atherosclerosis Increased arterial stiffness Peripheral artery disease Summary of recommendations on therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease Sexual dysfunction Resistant hypertension Carotid baroreceptor stimulation Renal denervation Other invasive approaches Follow-up in resistant hypertension Summary of recommendations on therapeutic strategies in patients with resistant hypertension Malignant hypertension Hypertensive emergencies and urgencies Perioperative management of hypertension Renovascular hypertension Primary aldosteronism Treatment of associated risk factors Lipid-lowering agents Antiplatelet therapy Treatment of hyperglycaemia Summary of recommendations on treatment of risk factors associated with hypertension Follow-up Follow-up of hypertensive patients Follow-up of subjects with high normal blood pressure and white-coat hypertension Elevated blood pressure at control visits Continued search for asymptomatic organ damage Can antihypertensive medications be reduced or stopped? Improvement of blood pressure control in hypertension Hypertension disease management Team approach in disease management Mode of care delivery The role of information and communication technologies 53 Gaps in evidence and need for future trials Appendix 1 Appendix 2 Acknowledgments References 1. INTRODUCTION 1.1 Principles The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) follow the guidelines jointly issued by the two societies in 2003 and 2007 [1,2]. Publication of a new document 6 years after the previous one was felt to be timely because, over this period, important studies have been conducted and many new results have been published on both the diagnosis and treatment of individuals with an elevated blood pressure (BP), making refinements, modifications and expansion of the previous recommendations necessary. The 2013 ESH/ESC guidelines continue to adhere to some fundamental principles that inspired the 2003 and 2007 guidelines, namely (i) to base recommendations on properly conducted studies identified from an extensive review of the literature, (ii) to consider, as the highest priority, data from randomized, controlled trials (RCTs) and their meta-analyses, but not to disregard—particularly when dealing with diagnostic aspects—the results of observational and other studies of appropriate scientific calibre, and (iii) to grade the level of scientific evidence and the strength of recommendations on major diagnostic and treatment issues as in European guidelines on other diseases, according to ESC recommendations (Tables 1 and 2). While it was not done in the 2003 and 2007 guidelines, providing the recommendation class and the level of evidence is now regarded as important for providing interested readers with a standard approach, by which to compare the state of knowledge across different fields of medicine. was that this on recommendations that on the of the on is not in because, for a of is and recommendations from and both of which be When this guidelines as and the of studies and evidence is in with is to a of and a of recommendations that be and by in their of of European of the in of the 2013 guidelines on hypertension have been by the and on their and of major of of forms be on the ESC and was a which was by and by two one by and by The was over during which the and with one the document was by European by and by be that the recommendations issued by the 2013 ESH/ESC guidelines on hypertension the state of the on as by and in for and the have been by and New aspects of new evidence on diagnostic and therapeutic aspects of the guidelines in many from the previous of the important Epidemiological data on hypertension and control in of the value of home blood pressure and of role for diagnosis and management of to ambulatory blood pressure of the of white-coat hypertension and masked on of cardiovascular risk asymptomatic organ damage and for total risk of the of asymptomatic blood and of the risk of and target in Hypertension in of antihypertensive and drug treatment of high normal for and target systolic blood pressure in both and risk approach to for New therapeutic for target on therapeutic strategies in special recommendations on treatment of hypertension in the treatment of to resistant hypertension and new treatment Increased to New approaches to chronic management of hypertensive Relationship of blood pressure to cardiovascular and renal damage The and and renal been in a of observational studies The in in the 2003 and 2007 ESH/ESC guidelines be as Office an with the of heart failure and peripheral artery disease as as of renal disease is at and in The with from high to of for and for to be a of after the of years and in elderly individuals pressure and been to have a role is by the high risk by patients with an elevated and a normal or systolic hypertension with is by out-of-office as by and The and and is by the of other risk Metabolic risk factors when is high when it is Definition and classification of hypertension The and and renal the and hypertension when on is because, in the and have a both to the diagnostic approach and to the The classification is from the 2003 and 2007 ESH/ESC guidelines Hypertension is as on the evidence from that in patients with and The classification is in and elderly different on in and for data from trials not on classification in and according to their and be in the on the evaluation and treatment of high in and and classification of blood pressure Prevalence of hypertension data on the of hypertension and the of in different European the of hypertension to be of the with a with to be in the across with changes in the to the of results and the of a of hypertension been is a hypertension is by the important of this of hypertension and for stroke been The and of stroke in have been by of European a in to European which a in from stroke Hypertension and total cardiovascular risk a hypertension guidelines on as the or the need the the and European Society recommendations on of heart disease in and that of be to of total (or approach is now and been the 2003 and 2007 ESH/ESC guidelines for the management of arterial hypertension [1,2]. The is on the that a of the hypertensive an of with the risk when and other risk factors to a total risk that is the of in high-risk antihypertensive treatment strategies and of of drug and as as other be different from to be in is evidence in high-risk control is and the combination of antihypertensive drugs with other as The therapeutic approach total risk in to in to of the management of Assessment of total cardiovascular risk of total risk is in of as with of cardiovascular disease or with elevated risk of the total risk is high or for a of patients with hypertension not to of the and the of at high or high risk the of to total risk, as to be to the therapeutic approach have been for total risk and limitations have been The been on European The the risk of from disease over years on total and The of the for which been done for European the two of one for high-risk and one for The of as Heart is to for the of on total The and their in risk assessment and management but be in the of the knowledge and with to the that total risk is associated with when with other strategies not been be in the subjects and with the risk associated with is in subjects in individuals and from with elevated an not the diagnostic for with and with a history of the of years in and years in total risk is as the risk of from of on in total risk be in the of high with risk this to a high-risk years treatment be by of risk or by heart and is in the European on in Clinical which is when been to of asymptomatic in in the which the risk that by the of risk is to for asymptomatic evidence for the risk of is a guidelines for the management of hypertension and 2003 Society of Hypertension Guidelines and the 2003 and 2007 ESH/ESC have risk in different on risk asymptomatic and of or chronic kidney disease as done by the ESC guidelines The classification in high and high risk is in the guidelines and to the risk of as by the ESC guidelines The factors on which the is in Table of total risk in of high and high risk according to and and of asymptomatic stage or with a high normal but a out-of-office have a risk in the hypertension with a high but normal out-of-office is or have risk hypertension for the for of total risk in Limitations for risk assessment have limitations that be The of in of risk is on the damage is on limitations be that the of total risk is to the of to that to grade in to the of risk is by or to a which treatment is be in that to high total risk is as as the of a value to this and at is a of on total risk is that adults to high-risk when have one major risk and a in many elderly a high total risk level at risk to their The consequences that in is and is to subjects at high risk the in the of their to an risk to a high and risk in with of their Summary of recommendations on total cardiovascular risk assessment cardiovascular risk The evaluation of a with hypertension (i) the diagnosis of (ii) of secondary and (iii) risk, and for measurement, history history, physical laboratory investigations and diagnostic of the investigations in in Bood pressure measurement Office or clinic blood pressure be a in not or be according to and their be in a laboratory of at the is and and be to the the of a and which been to an risk the with the be is by one a with measurement, it be to elderly patients and in other conditions in which be or it is that be 1 and 3 after of the as a reduction in of or in of 3 of been to a for and of in the with the in an isolated providing information be as a to and to by or be associated with measurement of heart heart or in hypertension for in Table Office blood pressure Out-of-office blood pressure The major of out-of-office is that it a of from the which a assessment of Out-of-office is by or by principles and for the two of in to recommendations for measurement The be to the with and in of appropriate of the results that the of out-of-office is for and but for the and for and and different information on the and risk and the two be regarded as or The with and is to Office is ambulatory and home and the as for the of hypertension for home and ambulatory according to the on in Table have been and according to and be properly and at 6 The be on of hypertension by and out-of-office blood pressure blood pressure aspects of aspects have been by the on Blood is with the a on the for a period, that it information on during and at during the of of the the the and from measurement by the not be the of a the be and The is to in normal but to from exercise at the of to and and the with the at heart The is to information in a on and that in to the of drug and and from at during the and be the of be that be at the during the and The to a and a of be of during and be or the be The of and the of have been to is not and be is that not be when the is and blood pressure to the and the in and be from the on the of the of and to is to in which the and from to for been that from to and from to 6 with the and but other have been as from to and from 1 to 6 the of different measurement during the and the and to for it is that be for the or to the of the to of The the and during the as the of a normal in a it is that the of a of of be as an to subjects as have been of and in that the of the is for of sleep sleep high in chronic kidney disease and of be from blood pressure and the ambulatory arterial stiffness their value is not and be regarded as with of in in and guidelines information on for in which the need for a an a to compare and a a of as of ambulatory studies have that hypertensive ventricular hypertrophy and other of with ambulatory with been to have a with or studies in which a value to ambulatory Evidence from of published observational studies and data that ambulatory in is a risk of as or and The of ambulatory been in the in and in and in and hypertensive in patients at high risk and in patients with or renal disease that for and in the that is a The is a of but information over and to the the is that the of is in patients with a in in with the of this the of the results for in have an risk for stroke data on the risk in and the of this is blood pressure aspects The on Blood a of recommendations for The of in some the of a or be on the not but their be in subjects with an diagnostic be on at and on in the as as in the is in a with the in the and after of and with two the results in a after by the not be which be by in a is the of with of the of and for be of of the results be the of the When with over or in the with ambulatory it over and is and it not data during and during or the of of home is to and of the studies in the in care and in hypertensive that the of and is with home with in which both and that home is at as with as is the ambulatory and that the of home is to that of ambulatory after for and White-coat (or isolated office) hypertension and masked (or isolated ambulatory) hypertension Office is of the which been to the a to the and in which to the a factors in or out-of-office be the the two is the or or clinic to the in which is elevated in the at visits and normal of the on or be normal in the and high of the which is or ambulatory The or and when both of measurement normal or the value for is the studies in white-coat or masked hypertension have a value of for out-of-office or home and for is the of white-coat or masked hypertension by or is that the and be to White-coat hypertension on the of white-coat hypertension and it to hypertensive subjects in to of white-coat hypertension and Prevalence is in the of target or when is on or when by a or The is to the level of for the of white-coat hypertension to in grade 1 hypertension and to in grade 3 hypertension is in white-coat hypertension in hypertension and studies have this to be the for subjects with white-coat hypertension be to individuals is an because, in some the risk of this was to be hypertension and in it was not different from when for and other The white-coat hypertensive patients the reduction of clinic to a reduced of Other factors to with in white-coat hypertensive (i) out-of-office is (ii) asymptomatic as be and (iii) this is the for metabolic risk factors and risk of diabetes and to hypertension is that the diagnosis of white-coat hypertension be and patients be and out-of-office Masked hypertension The of masked hypertension in studies factors out-of-office to as alcohol physical and history of hypertension and the is when is in the high normal Masked hypertension is associated with other risk asymptomatic and risk of diabetes and hypertension of studies that the of is two in and is to the in The that masked hypertension is and have to this patients masked hypertension is associated with an risk of when the during the Clinical indications for out-of-office blood pressure is now that out-of-office is an important to measurement, but the the for diagnosis and management of The value of to be important which have to the that out-of-office an important role in hypertension important and the choice the two in the on of assessment of the be in care and in it is to or on with which is the for out-of-office with the of providing not be with of in to for which is not be of or physical or be of or in which be as indications for out-of-office measurement for diagnostic in Table Clinical indications for out-of-office blood pressure measurement for diagnostic Blood pressure during exercise and laboratory stress during and the is for systolic for on a or a be with is on the normal during exercise of for and women been in a of but other of an to exercise have been the of at exercise is to arterial stiffness and and is in women in and in in individuals not have that an of during exercise the of hypertension in of at exercise to future hypertension is not of a of as of of and is on the of exercise with as after for and other as in as in hypertensive patients the results on the of exercise not which be to the that the two of in during is that the is a reduction of during with changes in and or not the arterial is an of at on subjects and in hypertensive patients with of an a the of normal hypertension be an for of with masked hypertension the other when hypertension is associated with dysfunction and of the of exercise be a during exercise a as in individuals in patients with disease or with heart failure in a exercise systolic the results the of during exercise for diagnostic and in patients with exercise is as a exercise and data and an of stress have been to stress and a of or laboratory stress in not stress and not have and to the results on the of the to with future hypertension not the is that to stress an on future risk of elevated ventricular atherosclerosis and The results that during stress not Central blood pressure The measurement of in hypertensive patients of both value for and the of antihypertensive with The arterial pressure is a of the pressure by ventricular and a be at the in the it the on kidney and The of be the as the the and systolic as a of the for heart to the of and pressure the arterial systolic and be different from the years and have been to systolic or pressure from pressure have been in an document studies in the that and by of and in patients with in the value of was or not in studies the guidelines, previous the measurement of and is of for in and is their The be in the in some of individuals at the level be to high of the pressure is normal Medical history The history the of the diagnosis of arterial and and and antihypertensive be to indications of secondary of Women be Hypertension an risk of renal and heart when a history of be in to assessment of risk, as or a history of heart or heart disease, with an on stroke and transient ischaemic attack history of the and of kidney and evidence for be history of hypertension is an important of to hypertension and and on and history in Table and Physical examination Physical examination to or the diagnosis of for secondary of hypertension and risk be as in and be to the diagnosis of at one to be at both and the two in in investigations of patients of the heart and renal renal on the of the and be with the and and heart be the is at heart an risk of heart the of on physical examination in Table Physical examination for secondary organ damage and Summary of recommendations on blood pressure history, and physical examination pressure history, and physical on Blood pressure history, and physical Laboratory investigations Laboratory investigations at providing evidence for the of risk for secondary hypertension and for the or of from the to the on laboratory investigations in Table Laboratory Genetics history is a in hypertensive patients with the to and in the of studies and been for ambulatory forms of hypertension have been as syndrome and a the of hypertension and the treatment hypertension is a with a studies and their to a total of which associated with systolic to risk for Searching for asymptomatic organ damage to the of asymptomatic as an stage in the of disease, and as a of risk, of organ be by appropriate be that a of evidence is now on the role of asymptomatic in the risk of individuals with and high The that of of and of is a in of assessment of in data from studies in different be is that the risk as the of Heart be of the assessment of hypertensive in is by the the or been in observational studies and trials to be an of the is at in patients over years of be to of ventricular or which risk and is when and ischaemic Atrial fibrillation is a and of in hypertensive patients of fibrillation the of by appropriate therapy not from is in and is to and renal risk in a of risk and in therapy evaluation of the in hypertensive patients of and and While ventricular for or the or of is according to the Society of the and risk is of for women and for for of of for in which to the of or been be in and patients in to to and of been that the is to by to the and that different for and women be by in subjects and in with with and with normal an of but is the of risk Hypertension is associated with of and as dysfunction is associated with and of heart when is normal failure with The and heart failure and but is not to the hypertensive and to recommendations it be with of the of the is of hypertensive heart disease the is reduced the and of dysfunction is on of and and the and and is an important of in a The of and of on and on The is to an of The value of is in the hypertensive and is associated with risk, of and in hypertensive patients of information and is a for the diagnosis of Left is by or been to be an of heart fibrillation and ischaemic stroke and for hypertensive heart disease for in Table The for in hypertension is to by that the on of and from control with the for by the Society of and the European of in the of for from in different be for in the assessment of and in patients with on and systolic and to systolic dysfunction of hypertensive patients assessment of systolic in hypertensive heart disease not information to at in the of a normal be in hypertensive patients in different and with different in hypertensive patients at total risk, it the risk evaluation by by in hypertensive patients with evidence of it the hypertrophy and and in hypertensive patients with it to is that assessment of and be of diagnostic value in patients with hypertension and be in hypertensive patients at the a or on and be for assessment of and when is not and when of have therapeutic consequences for diagnosis of in hypertensive patients with is hypertension the of exercise and exercise a normal and an value in patients of When the exercise is or an of as stress or stress is for a of for artery with normal associated with disease The of of and on the artery been to from isolated damage been to have an value in hypertension Blood vessels Carotid examination of the with measurement of the of been to the of both stroke and of risk factors both for the value at the and for the value at the level of the artery The and is a one and a for high risk is a been as a of in the 2007 Guidelines the value for high risk was in the elderly patients of the and in the patients of the European on and of a be identified by an or by a in of or of the value a value for of a and to other for and patients risk in the review that the value of be in asymptomatic individuals at

Rhinosinusitis is a significant and increasing health problem which results in a large financial burden on society. This evidence based position paper describes what is known about rhinosinusitis and nasal polyps, offers evidence based recommendations on diagnosis and treatment, and considers how we can make progress with research in this area. Rhinitis and sinusitis usually coexist and are concurrent in most individuals; thus, the correct terminology is now rhinosinusitis. Rhinosinusitis (including nasal polyps) is defined as inflammation of the nose and the paranasal sinuses characterised by two or more symptoms, one of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip), +/- facial pain/pressure, +/- reduction or loss of smell; and either endoscopic signs of polyps and/or mucopurulent discharge primarily from middle meatus and/or; oedema/mucosal obstruction primarily in middle meatus, and/or CT changes showing mucosal changes within the ostiomeatal complex and/or sinuses. The paper gives different definitions for epidemiology, first line and second line treatment and for research. Furthermore the paper describes the anatomy and (patho)physiology, epidemiology and predisposing factors, inflammatory mechanisms, evidence based diagnosis, medical and surgical treatment in acute and chronic rhinosinusitis and nasal polyposis in adults and children. Evidence based schemes for diagnosis and treatment are given for the first and second line clinicians. Moreover attention is given to complications and socio-economic cost of chronic rhinosinusitis and nasal polyps. Last but not least the relation to the lower airways is discussed.

Worldwide commercial interest in carbon nanotubes (CNTs) is reflected in a production capacity that presently exceeds several thousand tons per year. Currently, bulk CNT powders are incorporated in diverse commercial products ranging from rechargeable batteries, automotive parts, and sporting goods to boat hulls and water filters. Advances in CNT synthesis, purification, and chemical modification are enabling integration of CNTs in thin-film electronics and large-area coatings. Although not yet providing compelling mechanical strength or electrical or thermal conductivities for many applications, CNT yarns and sheets already have promising performance for applications including supercapacitors, actuators, and lightweight electromagnetic shields.

With the continued interest in the role of the gut microbiota in health, attention has now turned to how to harness the microbiota for the benefit of the host. This Consensus Statement outlines the definition and scope of the term 'prebiotic' as determined by an expert panel convened by the International Scientific Association for Probiotics and Prebiotics in December 2016. In December 2016, a panel of experts in microbiology, nutrition and clinical research was convened by the International Scientific Association for Probiotics and Prebiotics to review the definition and scope of prebiotics. Consistent with the original embodiment of prebiotics, but aware of the latest scientific and clinical developments, the panel updated the definition of a prebiotic: a substrate that is selectively utilized by host microorganisms conferring a health benefit. This definition expands the concept of prebiotics to possibly include non-carbohydrate substances, applications to body sites other than the gastrointestinal tract, and diverse categories other than food. The requirement for selective microbiota-mediated mechanisms was retained. Beneficial health effects must be documented for a substance to be considered a prebiotic. The consensus definition applies also to prebiotics for use by animals, in which microbiota-focused strategies to maintain health and prevent disease is as relevant as for humans. Ultimately, the goal of this Consensus Statement is to engender appropriate use of the term 'prebiotic' by relevant stakeholders so that consistency and clarity can be achieved in research reports, product marketing and regulatory oversight of the category. To this end, we have reviewed several aspects of prebiotic science including its development, health benefits and legislation.

BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS: We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weight plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses, followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placebo; or ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses plus placebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent. Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage. The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group versus the ipilimumab group. RESULTS: At a minimum follow-up of 36 months, the median overall survival had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.55 [P<0.001]; hazard ratio for death with nivolumab vs. ipilimumab, 0.65 [P<0.001]). The overall survival rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group, as compared with 34% in the ipilimumab group. The safety profile was unchanged from the initial report. Treatment-related adverse events of grade 3 or 4 occurred in 59% of the patients in the nivolumab-plus-ipilimumab group, in 21% of those in the nivolumab group, and in 28% of those in the ipilimumab group. CONCLUSIONS: Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with ipilimumab alone. (Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505 .).

BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily). The primary end point was investigator-assessed progression-free survival. RESULTS: The median progression-free survival was significantly longer with osimertinib than with standard EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001). The objective response rate was similar in the two groups: 80% with osimertinib and 76% with standard EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P=0.24). The median duration of response was 17.2 months (95% CI, 13.8 to 22.0) with osimertinib versus 8.5 months (95% CI, 7.3 to 9.8) with standard EGFR-TKIs. Data on overall survival were immature at the interim analysis (25% maturity). The survival rate at 18 months was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with standard EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P=0.007 [nonsignificant in the interim analysis]). Adverse events of grade 3 or higher were less frequent with osimertinib than with standard EGFR-TKIs (34% vs. 45%). CONCLUSIONS: Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125 .).

This article provides a classification of primary progressive aphasia (PPA) and its 3 main variants to improve the uniformity of case reporting and the reliability of research results. Criteria for the 3 variants of PPA--nonfluent/agrammatic, semantic, and logopenic--were developed by an international group of PPA investigators who convened on 3 occasions to operationalize earlier published clinical descriptions for PPA subtypes. Patients are first diagnosed with PPA and are then divided into clinical variants based on specific speech and language features characteristic of each subtype. Classification can then be further specified as "imaging-supported" if the expected pattern of atrophy is found and "with definite pathology" if pathologic or genetic data are available. The working recommendations are presented in lists of features, and suggested assessment tasks are also provided. These recommendations have been widely agreed upon by a large group of experts and should be used to ensure consistency of PPA classification in future studies. Future collaborations will collect prospective data to identify relationships between each of these syndromes and specific biomarkers for a more detailed understanding of clinicopathologic correlations.

The synergistic action of cytosolic Ca2+ and inositol 1,4,5-trisphosphate (InsP3) in releasing intracellular Ca2+ stores has been suggested to be responsible for the complex intracellular Ca2 signals observed during hormonal stimulation of many cell types. However, the ability of cytosolic Ca2+ to potentiate Ca2+ release has recently been questioned because of the observed inhibitory effects of Ca2+ chelators used in previous studies. In the present study, EGTA and BAPTA [1,2-bis-(2-amino-phenoxy)ethane- NNN'N'-tetra-acetic acid] poorly inhibited InsP3-induced Ca2+ release from permeabilized A7r5 smooth-muscle cells. Additionally, stimulatory effects of cytosolic and luminal Ca2+ were observed either in the complete absence of Ca2+ chelator or at constant Ca(2+)-free chelator concentration. These data suggest that potentiation of InsP3-induced Ca2+ release by Ca2+ in A7r5 cells reflects an interaction between Ca2+ and InsP3 receptors, rather than a decrease in chelator-dependent inhibition. The EC50 for activation of InsP3-induced Ca2+ release by cytosolic Ca2+ was unaffected by ATP, or by changing InsP3 concentration, although InsP3-induced Ca2+ release became less sensitive to the inhibitory effects of cytosolic Ca2+ as the InsP3 concentration was elevated. Increasing H+ or Mg2+ concentration shifted the Ca(2+)-activation curve towards higher Ca2+ concentrations. These data suggest that, in addition to the InsP3-binding site, the affinity of the Ca(2+)-binding site(s) on InsP3 receptors can be modulated by intracellular cations.

Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments. With a number of recent technological improvements, PDT has the potential to become integrated into the mainstream of cancer treatment.

Assessing the applicability of frameworks developed in one country to other countries is an important step in establishing the generalizability of consumer behavior theories. In order for such comparisons to be meaningful, however, the instruments used to measure the theoretical constructs of interest have to exhibit adequate cross-national equivalence. We review the various forms of measurement invariance that have been proposed in the literature, organize them into a coherent conceptual framework that ties different requirements of measure equivalence to the goals of the research, and propose a practical, sequential testing procedure for assessing measurement invariance in cross-national consumer research. The approach is based on multisample confirmatory factor analysis and clarifies under what conditions meaningful comparisons of construct conceptualizations, construct means, and relationships between constructs are possible. An empirical application dealing with the single-factor construct of consumer ethnocentrism in Belgium, Great Britain, and Greece is provided to illustrate the procedure.

A new approach to the problem of multimodality medical image registration is proposed, using a basic concept from information theory, mutual information (MI), or relative entropy, as a new matching criterion. The method presented in this paper applies MI to measure the statistical dependence or information redundancy between the image intensities of corresponding voxels in both images, which is assumed to be maximal if the images are geometrically aligned. Maximization of MI is a very general and powerful criterion, because no assumptions are made regarding the nature of this dependence and no limiting constraints are imposed on the image content of the modalities involved. The accuracy of the MI criterion is validated for rigid body registration of computed tomography (CT), magnetic resonance (MR), and photon emission tomography (PET) images by comparison with the stereotactic registration solution, while robustness is evaluated with respect to implementation issues, such as interpolation and optimization, and image content, including partial overlap and image degradation. Our results demonstrate that subvoxel accuracy with respect to the stereotactic reference solution can be achieved completely automatically and without any prior segmentation, feature extraction, or other preprocessing steps which makes this method very well suited for clinical applications.